Why Nektar Therapeutics Is On Investors’ Radar Today

Nektar Therapeutics (NKTR) has caught investor attention after a period where its shares showed strong moves over the past month and past 3 months, contrasting with mixed shorter term returns.

At a share price of $68.36, Nektar’s recent 30 day share price return of 83.12% and year to date share price return of 57.44% sit alongside a very large 1 year total shareholder return. This suggests momentum has recently picked up after a weak 5 year total shareholder return.

If Nektar’s recent move has you thinking about what else is moving, this is a good moment to scan our screener of 28 healthcare AI stocks for more ideas in the space.

With Nektar posting strong recent returns but still trading well below the average analyst price target of $129.86, you have to ask yourself: is there real value left here, or is the market already pricing in future growth?

Most Popular Narrative: 45% Undervalued

With Nektar Therapeutics last closing at $68.36 and the most followed narrative pointing to a fair value of $123.43, the gap between price and story is wide enough to pay attention to.

Robust cash position after the recent equity raise extends runway into 2027, providing operational stability to advance late-stage assets and initiate Phase III trials without near-term dilution or financing risk, which supports earnings predictability and reduces financial leverage concerns.

Broadening of pipeline applications (e.g., immunology, autoimmune, dermatology) and the prospect of international partnerships or strategic out-licensing align with the global expansion of healthcare access, providing opportunities for diversified and growing revenue streams in coming years.

Want to see what sits behind that nearly two times gap to fair value? Revenue expectations, margins, and future multiples all pull in different directions. The narrative spells out exactly which pieces need to fall into place for that higher value to make sense.

Result: Fair Value of $123.43 (UNDERVALUED)

However, the story still hinges on REZPEG delivering clean, statistically robust data, and on Nektar managing funding needs without excessive dilution if timelines slip.

Another Angle On Valuation

The narrative flags Nektar as 45% undervalued, yet its current P/S of 30.6x is far above the US Pharmaceuticals average of 4.2x, the peer average of 12.7x, and even the fair ratio of 12.7x. That kind of premium can signal potential upside or just a lot of expectation. Which do you think it is?

Next Steps

Curious whether the optimism in this story outweighs the concerns, or the other way around? Take a moment to look through the data, weigh both the risks and potential rewards, and use 2 key rewards and 4 important warning signs to shape your own view while the market is still reacting.

Ready To Hunt For Your Next Idea?

If this story has sharpened your curiosity, do not stop here. Your next strong idea could be sitting in plain sight just outside Nektar’s ticker symbol.

• Target reliable income by scanning companies that show up as 13 dividend fortresses, so you can focus on payouts backed by fundamental data.
• Spot potential mispricings using the list of 45 high quality undervalued stocks and see which names the numbers suggest may be trading out of step with their fundamentals.
• Prioritise resilience first with a filter of 76 resilient stocks with low risk scores, helping you focus on companies where our model flags fewer red flags.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.